vs
EXACT SCIENCES CORP（EXAS）与Ubiquiti Inc.（UI）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Ubiquiti Inc.的1.1倍（$878.4M vs $814.9M），Ubiquiti Inc.净利率更高（28.7% vs -9.8%，领先38.5%），Ubiquiti Inc.同比增速更快（35.8% vs 23.1%），Ubiquiti Inc.自由现金流更多（$260.3M vs $120.4M），过去两年Ubiquiti Inc.的营收复合增速更高（28.6% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Ubiquiti Inc.是一家美国科技企业，2003年于加利福尼亚州圣何塞成立，目前总部位于纽约。公司旗下拥有多个品牌，主营面向企业及家庭用户的有线、无线数据通信产品的研发、生产与销售。
EXAS vs UI — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$814.9M
营收增速更快
UI
高出12.7%
23.1%
净利率更高
UI
高出38.5%
-9.8%
自由现金流更多
UI
多$139.8M
$120.4M
两年增速更快
UI
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $814.9M |
| 净利润 | $-86.0M | $233.6M |
| 毛利率 | 70.1% | 45.9% |
| 营业利润率 | -9.4% | 35.9% |
| 净利率 | -9.8% | 28.7% |
| 营收同比 | 23.1% | 35.8% |
| 净利润同比 | 90.1% | 70.8% |
| 每股收益（稀释后） | $-0.45 | $3.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASUI
| Q4 25 | $878.4M | $814.9M | ||
| Q3 25 | $850.7M | $733.8M | ||
| Q2 25 | $811.1M | $759.2M | ||
| Q1 25 | $706.8M | $664.2M | ||
| Q4 24 | $713.4M | $599.9M | ||
| Q3 24 | $708.7M | $550.3M | ||
| Q2 24 | $699.3M | $507.5M | ||
| Q1 24 | $637.5M | $493.0M |
净利润EXASUI
| Q4 25 | $-86.0M | $233.6M | ||
| Q3 25 | $-19.6M | $207.9M | ||
| Q2 25 | $-1.2M | $266.7M | ||
| Q1 25 | $-101.2M | $180.4M | ||
| Q4 24 | $-864.6M | $136.8M | ||
| Q3 24 | $-38.2M | $128.0M | ||
| Q2 24 | $-15.8M | $103.8M | ||
| Q1 24 | $-110.2M | $76.3M |
毛利率EXASUI
| Q4 25 | 70.1% | 45.9% | ||
| Q3 25 | 68.6% | 46.0% | ||
| Q2 25 | 69.3% | 45.1% | ||
| Q1 25 | 70.8% | 44.5% | ||
| Q4 24 | 69.0% | 41.2% | ||
| Q3 24 | 69.4% | 42.1% | ||
| Q2 24 | 69.8% | 40.2% | ||
| Q1 24 | 70.0% | 35.3% |
营业利润率EXASUI
| Q4 25 | -9.4% | 35.9% | ||
| Q3 25 | -3.0% | 35.7% | ||
| Q2 25 | -0.3% | 34.4% | ||
| Q1 25 | -13.6% | 34.2% | ||
| Q4 24 | -122.8% | 29.8% | ||
| Q3 24 | -5.6% | 30.7% | ||
| Q2 24 | -3.8% | 27.3% | ||
| Q1 24 | -16.7% | 22.6% |
净利率EXASUI
| Q4 25 | -9.8% | 28.7% | ||
| Q3 25 | -2.3% | 28.3% | ||
| Q2 25 | -0.1% | 35.1% | ||
| Q1 25 | -14.3% | 27.2% | ||
| Q4 24 | -121.2% | 22.8% | ||
| Q3 24 | -5.4% | 23.3% | ||
| Q2 24 | -2.3% | 20.5% | ||
| Q1 24 | -17.3% | 15.5% |
每股收益（稀释后）EXASUI
| Q4 25 | $-0.45 | $3.86 | ||
| Q3 25 | $-0.10 | $3.43 | ||
| Q2 25 | $-0.01 | $4.40 | ||
| Q1 25 | $-0.54 | $2.98 | ||
| Q4 24 | $-4.69 | $2.26 | ||
| Q3 24 | $-0.21 | $2.12 | ||
| Q2 24 | $-0.09 | $1.72 | ||
| Q1 24 | $-0.60 | $1.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $302.8M |
| 总债务越低越好 | — | $47.5M |
| 股东权益账面价值 | $2.4B | $1.0B |
| 总资产 | $5.9B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资EXASUI
| Q4 25 | $964.7M | $302.8M | ||
| Q3 25 | $1.0B | $177.2M | ||
| Q2 25 | $858.4M | $149.7M | ||
| Q1 25 | $786.2M | $151.0M | ||
| Q4 24 | $1.0B | $133.1M | ||
| Q3 24 | $1.0B | $165.2M | ||
| Q2 24 | $946.8M | $126.3M | ||
| Q1 24 | $652.1M | $102.5M |
总债务EXASUI
| Q4 25 | — | $47.5M | ||
| Q3 25 | — | $133.8M | ||
| Q2 25 | — | $250.0M | ||
| Q1 25 | — | $340.0M | ||
| Q4 24 | — | $406.3M | ||
| Q3 24 | — | $552.5M | ||
| Q2 24 | — | $708.1M | ||
| Q1 24 | — | $877.5M |
股东权益EXASUI
| Q4 25 | $2.4B | $1.0B | ||
| Q3 25 | $2.5B | $828.4M | ||
| Q2 25 | $2.5B | $668.3M | ||
| Q1 25 | $2.4B | $436.1M | ||
| Q4 24 | $2.4B | $290.4M | ||
| Q3 24 | $3.2B | $188.1M | ||
| Q2 24 | $3.2B | $95.1M | ||
| Q1 24 | $3.1B | $25.9M |
总资产EXASUI
| Q4 25 | $5.9B | $1.6B | ||
| Q3 25 | $5.9B | $1.5B | ||
| Q2 25 | $5.8B | $1.5B | ||
| Q1 25 | $5.7B | $1.3B | ||
| Q4 24 | $5.9B | $1.2B | ||
| Q3 24 | $6.7B | $1.2B | ||
| Q2 24 | $6.7B | $1.2B | ||
| Q1 24 | $6.4B | $1.2B |
负债/权益比EXASUI
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 7.45× | ||
| Q1 24 | — | 33.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $263.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $260.3M |
| 自由现金流率自由现金流/营收 | 13.7% | 31.9% |
| 资本支出强度资本支出/营收 | 3.6% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $699.5M |
8季度趋势，按日历期对齐
经营现金流EXASUI
| Q4 25 | $151.7M | $263.9M | ||
| Q3 25 | $219.9M | $198.5M | ||
| Q2 25 | $89.0M | $130.4M | ||
| Q1 25 | $30.8M | $123.6M | ||
| Q4 24 | $47.1M | $152.4M | ||
| Q3 24 | $138.7M | $233.7M | ||
| Q2 24 | $107.1M | $231.4M | ||
| Q1 24 | $-82.3M | $163.9M |
自由现金流EXASUI
| Q4 25 | $120.4M | $260.3M | ||
| Q3 25 | $190.0M | $193.3M | ||
| Q2 25 | $46.7M | $125.2M | ||
| Q1 25 | $-365.0K | $120.7M | ||
| Q4 24 | $10.7M | $150.4M | ||
| Q3 24 | $112.6M | $231.1M | ||
| Q2 24 | $71.2M | $229.5M | ||
| Q1 24 | $-120.0M | $160.6M |
自由现金流率EXASUI
| Q4 25 | 13.7% | 31.9% | ||
| Q3 25 | 22.3% | 26.3% | ||
| Q2 25 | 5.8% | 16.5% | ||
| Q1 25 | -0.1% | 18.2% | ||
| Q4 24 | 1.5% | 25.1% | ||
| Q3 24 | 15.9% | 42.0% | ||
| Q2 24 | 10.2% | 45.2% | ||
| Q1 24 | -18.8% | 32.6% |
资本支出强度EXASUI
| Q4 25 | 3.6% | 0.4% | ||
| Q3 25 | 3.5% | 0.7% | ||
| Q2 25 | 5.2% | 0.7% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.1% | 0.3% | ||
| Q3 24 | 3.7% | 0.5% | ||
| Q2 24 | 5.1% | 0.4% | ||
| Q1 24 | 5.9% | 0.7% |
现金转化率EXASUI
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | 0.95× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.68× | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | 1.83× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | — | 2.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
UI
| Enterprise Technology | $729.0M | 89% |
| Service Provider Technology | $85.9M | 11% |
